Cell Therapy News/Articles, page-17261

The pity of this is that countless lives of Heart Failure patients could've been saved by the protection that Meso's cells could've given to heart failure patients. Dr Perin first injected patients with Meso's cells back in 2004 and has been running trials ever since. He freely admitted that if he had chosen a different endpoint for the DREAM heart trial (such as reduction in Heart Attacks, Strokes, Cardiac Death or reduction of days in hospital for MACE) then it would've been seen as a huge success and would've changed the global treatment of heart failure patients, especially those with high inflammation markers. He chose to go with a more conservative EP of reducing days in hospital for heart failure because nobody had ever before recorded the amazing results that Meso subsequently achieved in stroke, heart attack etc. As it turned out, reducing days in hospital for heart failure is difficult because the short term volume overload problem is controlled by existing drugs, and to show a statistical benefit of the cells would have required a much larger trial. The next trial will be heart attack, stroke, cardiac death and hospitalisations due to MACE (not due to heart failure) in heart failure patients with reduced LVEF. Meso's cells even improve the rLVEF - which was a surprise and implies some heart function repair. We are all losing loved ones because of the cloth-eared and muddle-headed FDA. There should at least have been an AA for LVAD patients, yet we wait.

Aloha.